Patents by Inventor Jonathan M. Gershoni
Jonathan M. Gershoni has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20230321218Abstract: The present invention relates to vaccines and therapeutic compositions targeted at coronaviruses, specifically, the Severe Acute Respiratory Syndrome coronavirus 2 (SARS CoV2). More specifically, the invention provides reconstituted Receptor Binding Motif (RBM) of a Spike protein of the SARS CoV2, Receptor Binding domains (RBDs), and spike proteins comprising the reconstituted RBMs or ?-linkers, compositions, vaccines, therapeutic and diagnostic methods and uses thereof.Type: ApplicationFiled: April 7, 2021Publication date: October 12, 2023Inventor: Jonathan M. GERSHONI
-
Patent number: 8715684Abstract: A novel peptides are complexed with HIV-I envelope protein gp120, and causes the protein to assume a CD4i conformation but without occluding the CD4 binding-site of gp120. This peptide-gp120 complex is immunogenic and, upon immunization of subjects, induces broadly-neutralizing antibodies directed to the CD4 binding site of gp120. The peptide preferably consists of a sequence of 8-20 amino acid residues which comprises (a) a core sequence Arg-Xaa1-Asp-Leu-Pro-Xaa2-Trp-Ala (SEQ ID NO: 1) in which Xaa1 and Xaa2 is any amino acid, or (b) certain substitution variants of SEQ ID NO:1.Type: GrantFiled: August 28, 2008Date of Patent: May 6, 2014Assignee: Ramot at Tel Aviv University Ltd.Inventors: Jonathan M. Gershoni, Gal Dela
-
Publication number: 20100247558Abstract: A novel peptides are complexed with HIV-I envelope protein gp120, and causes the protein to assume a CD4i conformation but without occluding the CD4 binding-site of gp120. This peptide-gp120 complex is immunogenic and, upon immunization of subjects, induces broadly-neutralizing antibodies directed to the CD4 binding site of gp120. The peptide preferably consists of a sequence of 8-20 amino acid residues which comprises (a) a core sequence Arg-Xaa1-Asp-Leu-Pro-Xaa2-Trp-Ala (SEQ ID NO: 1) in which Xaa1 and Xaa2 is any amino acid, or (b) certain substitution variants of SEQ ID NO:1.Type: ApplicationFiled: August 28, 2008Publication date: September 30, 2010Applicant: Ramot at Tel Aviv University Ltd.Inventors: Jonathan M. Gershoni, Gal Dela
-
Patent number: 7587281Abstract: The structure of conformational, discontinuous binding surfaces that associate with a binding molecule, preferably the epitopes of monoclonal antibodies (mAbs) may be discovered. The binding molecule is used to select specific peptides from a peptide library that, in turn, are used as a binding surface (epitope) defining database that is applied via a novel computer algorithm to analyze the crystalline-structure of the original binding surface (antigen). An antigenic epitope-mimetic that is recognized by its original mAb may be reconstituted based on the segments of the epitope identified in the prediction. The basic elements of the binding domain on gp120 that is recognized by broadly neutralizing antibody b12 are disclosed, as in their use in making vaccines for preventing or treating HIV.Type: GrantFiled: March 8, 2006Date of Patent: September 8, 2009Assignee: Ramot At Tel Aviv UniversityInventors: Jonathan M. Gershoni, Erez Bublil, Dimitri Denisov, Galina Denisova
-
Patent number: 6984488Abstract: Methods of using overlapping peptides for the discovery of discontinuous epitopes, as vaccines, for drug design, for diagnostic purposes and for the elucidation of three-dimensional protein structure. Specifically, these methods can be used to map conformational epitopes using overlapping peptides. The methods are both complete, yet more specific than random phage libraries. They can also be used to develop DNA vaccines which exploit the concept of overlapping peptides in a variety of expression systems. Conformational epitopes prepared with these methods can be used for preparing antibodies, as components of diagnostic tools, and for elucidating three-dimensional protein structure.Type: GrantFiled: November 4, 1997Date of Patent: January 10, 2006Assignee: Ramot at Tel-Aviv University Ltd.Inventors: Jonathan M. Gershoni, David Enshel
-
Patent number: 6812026Abstract: Binding of two members of a binding couple reveal epitopes which are revealed only after binding and the monoclonal antibody secreted from the hybridoma cell line CG-10 directed against these epitopes bind to the bound couple at a significantly higher affinity than their binding affinity to either of the two members themselves when not bound to one another.Type: GrantFiled: December 19, 2001Date of Patent: November 2, 2004Assignee: Ramot at Tel-Aviv University Ltd.Inventor: Jonathan M. Gershoni
-
Patent number: 6465241Abstract: A nucleic acid accumulation analyzing chip comprising an optical waveguide having a radiation input port and a radiation output port, the optical waveguide being formed with at least one optical microcavity along its optical path, at least one oligonucleotide being immobilized to the optical waveguide in the microcavity, such that when the at least one oligonucleotide is contacted with reaction reagents under conditions allowing a nucleic acid accumulation reaction to take place, accumulated nucleic acid is detectable by providing radiation at the radiation input port of the optical waveguide and monitoring radiation signal modulation at the radiation output port of the optical waveguide.Type: GrantFiled: December 14, 2000Date of Patent: October 15, 2002Assignee: Ramot University Authority for Applied Research and Industrial Development Ltd.Inventors: Dan Haronian, Menachem Nathan, Jonathan M. Gershoni, Arieh Yaron
-
Publication number: 20020081576Abstract: Binding of two members of a binding couple reveal epitopes which art revealed only after binding and antibodies directed against these epitopes bind to the bound couple at a significantly higher affinity than their binding affinity to either of the two members themselves when not bound to one another. The novel epitope and the antibodies of the invention have various therapeutic and diagnostic applications such as treatment and immunization against viral diseases.Type: ApplicationFiled: December 19, 2001Publication date: June 27, 2002Applicant: Ramot University for Applied Research and Industrial Development Ltd.Inventor: Jonathan M. Gershoni
-
Patent number: 6410318Abstract: Binding of two members of a binding couple reveals epitopes which are revealed only after binding and the monoclonal antibody secreted from the hybridoma cell line CG-10 directed against these epitopes bind to the bound couple at a significantly higher affinity than their binding affinity to either of the two members themselves when not bound to one another.Type: GrantFiled: August 24, 2000Date of Patent: June 25, 2002Assignee: Ramot University for Applied Research and Industrial Development Ltd.Inventor: Jonathan M. Gershoni
-
Publication number: 20020061519Abstract: A nucleic acid accumulation analyzing chip comprising an optical waveguide having a radiation input port and a radiation output port, the optical waveguide being formed with at least one optical microcavity along its optical path, at least one oligonucleotide being immobilized to the optical waveguide in the microcavity, such that when the at least one oligonucleotide is contacted with reaction reagents under conditions allowing a nucleic acid accumulation reaction to take place, accumulated nucleic acid is detectable by providing radiation at the radiation input port of the optical waveguide and monitoring radiation signal modulation at the radiation output port of the optical waveguide.Type: ApplicationFiled: December 14, 2000Publication date: May 23, 2002Inventors: Dan Haronian, Menachem Nathan, Jonathan M. Gershoni, Arieh Yaron
-
Patent number: 6329202Abstract: Binding of two members of a binding couple reveals epitopes which are revealed only after binding and the monoclonal antibody secreted from the hybridoma cell line CG-10 directed against these epitopes bind to the bound couple at a significantly higher affinity than their binding affinity to either of the two members themselves when not bound to one another.Type: GrantFiled: August 24, 2000Date of Patent: December 11, 2001Assignee: Ramot University Authority for Applied Research and Industrial Development Ltd.Inventor: Jonathan M. Gershoni
-
Patent number: 6165722Abstract: A method of preparing a bimolecular interaction library for a first biological unit and for a second biological unit, each of the first and second biological units having a corresponding genetic material, the method comprising the steps of: (a) preparing a first fragment from the genetic material corresponding to the first biological unit; (b) preparing a first phage library having a first selection marker with the first fragment, such that a first peptide is displayed by the first phage library; (c) preparing a second fragment from the genetic material corresponding to the second biological unit; (d) preparing a second phage library having a second selection marker with the second fragment, such that a second peptide is displayed by the second phage library; (e) mixing the first phage library and the second phage library; and (f) co-selecting co-selected phages from the first phage library and from the second phage library by the first selection marker and the second selection marker when a selection processType: GrantFiled: May 6, 1999Date of Patent: December 26, 2000Assignee: Ramot University Authority for Applied Research & Industrial Development Ltd.Inventors: Jonathan M. Gershoni, David Enshel
-
Patent number: 6143876Abstract: Binding of two members of a binding couple reveals epitopes which are revealed only after binding and the monoclonal antibody secreted from the hybridoma cell line CG-10 directed against these epitopes bind to the bound couple at a significantly higher affinity than their binding affinity to either of the two members themselves when not bound to one another.Type: GrantFiled: November 4, 1999Date of Patent: November 7, 2000Assignee: Ramot University Authority for Applied Research and Industrial Development Ltd.Inventor: Jonathan M. Gershoni
-
Patent number: 6020468Abstract: Binding of two members of a binding couple reveals epitopes which are revealed only after binding and the monoclonal antibody secreted from the hybridoma cell line CG-10 directed against these epitopes bind to the bound couple at a significantly higher affinity than their binding affinity to either of the two members themselves when not bound to one another.Type: GrantFiled: January 22, 1999Date of Patent: February 1, 2000Assignee: Ramot University Authority for Applied Research and Industrial Development Ltd.Inventor: Jonathan M. Gershoni
-
Patent number: 5925741Abstract: Binding of two members of a binding couple reveals epitopes which are revealed only after binding and the monoclonal antibody secreted from the hybridoma cell line CG-10 directed against these epitopes bind to the bound couple at a significantly higher affinity than their binding affinity to either of the two members themselves when not bound to one another.Type: GrantFiled: July 31, 1995Date of Patent: July 20, 1999Assignee: Ramot University Authority for Applied Research and Industrial Development Ltd.Inventor: Jonathan M. Gershoni
-
Patent number: 5770572Abstract: Molecular decoyants are chemical structures which functionally resemble an endogenous receptor. They may be used for the treatment of humans or other animals which have been subjected to a foreign agent which exerts an undesired effect only after first binding to that endogenous receptor. A decoyant is a fraction of an endogenous receptor which retains the essential elements of the binding site of the receptor for the foreign agent or is a synthetic or biosynthetic derivative thereof. The .alpha.184-200 amino acid sequence of Torpedo californica acetylcholine receptor is an example of a decoyant which protects against curarimimetic neurotoxins. Another example is the fraction of the CD4 receptor which retains the essential elements of the receptor for protection against HIV.Type: GrantFiled: June 30, 1989Date of Patent: June 23, 1998Inventor: Jonathan M. Gershoni
-
Patent number: 4601828Abstract: The method of transfer of macromolecules such as nucleic acid and proteins from a chromatographic substrate to an immobilizing matrix uses as the immobilizing matrix, a charge modified microporous membrane comprising an organic microporous membrane having a charge modifying amount of a cationic charge modifying agent bonded to substantially all of the wetted surfaces of said membrane. The charge modified microporous membrane can also be a reinforced microporous membrane, preferably a porous reinforcing web impregnated with a polymeric microporous membrane. A nucleic acid or protein blotting product comprising a chromatographic matrix having the charge modified microporous membrane on a surface thereof is also provided.Type: GrantFiled: January 4, 1985Date of Patent: July 22, 1986Assignee: Yale UniversityInventor: Jonathan M. Gershoni
-
Patent number: 4512896Abstract: The method of transfer of macromolecules such as nucleic acid and proteins from a chromatographic substrate to an immobilizing matrix uses as the immobilizing matrix, a charge modified microporous membrane comprising an organic microporous membrane having a charge modifying amount of a cationic charge modifying agent bonded to substantially all of the wetted surfaces of said membrane. The charge modified microporous membrane can also be a reinforced microporous membrane, preferably a porous reinforcing web impregnated with a polymeric microporous membrane. A nucleic acid or protein blotting product comprising a chromatographic matrix having the charge modified microporous membrane on a surface thereof is also provided.Type: GrantFiled: February 7, 1983Date of Patent: April 23, 1985Assignee: Yale UniversityInventor: Jonathan M. Gershoni